Structure-activity relationships for the binding of polymyxins with human α-1-acid glycoprotein

Biochemical Pharmacology

Volumn 84, Issue 3, 2012, Pages 278-291

  Azad, Mohammad A K ^a   Huang, Johnny X ^b   Cooper, Matthew A ^b   Roberts, Kade D ^a   Thompson, Philip E ^a   Nation, Roger L ^a   Li, Jian ^a   Velkov, Tony ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Binding affinity; Colistin; Human 1 acid glycoprotein; Polymyxin

Indexed keywords

ANTIBIOTIC AGENT; CHLORPROMAZINE; COLISTIN; COLISTIN METHANSULFONATE; COLISTIN NONA PEPTIDE; DIAMINOBUTYRIC ACID; DIAZEPAM; OROSOMUCOID; POLYMYXIN; POLYMYXIN B; POLYMYXIN B3; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; DRUG PROTEIN BINDING; DRUG STRUCTURE; FLUOROMETRY; ISOTHERMAL TITRATION CALORIMETRY; PRIORITY JOURNAL; PROTEIN MOTIF; STRUCTURE ACTIVITY RELATION;

HUMANS; OROSOMUCOID; POLYMYXIN B; POLYMYXINS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84861988927     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.05.004     Document Type: Article

References (76)

1. Flower DR. The lipocalin protein family: structure and function. Biochem J 1996;318(Pt 1):1-14. (Pubitemid 26283618)
2. Flower DR, North AC, Sansom CE. The lipocalin protein family: structural and sequence overview. Biochim Biophys Acta 2000;1482:9-24.
3. Skerra A. Lipocalins as a scaffold. Biochim Biophys Acta 2000;1482:337-50.
4. Fournier T, Medjoubi NN, Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta 2000;1482:157-71.
5. Hochepied T, Berger FG, Baumann H, Libert C. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev 2003;14:25-34. (Pubitemid 36098429)
6. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 2001;33:161-235. (Pubitemid 32703255)
7. Kremer JM, Wilting J, Janssen LH. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988;40:1-47.
8. Ojala PJ, Hermansson M, Tolvanen M, Polvinen K, Hirvonen T, Impola U, et al. Identification of alpha-1 acid glycoprotein as a lysophospholipid binding protein: a complementary role to albumin in the scavenging of lysophosphatidylcholine. Biochemistry 2006;45:14021-31. (Pubitemid 44846191)
9. Zsila F, Mady G. Biliverdin is the endogenous ligand of human serum alpha(1)-acid glycoprotein. Biochem Biophys Res Commun 2008;372:503-7.
10. Otagiri M. A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab Pharmacokinet 2005;20:309-23.
11. Kristensen CB. Imipramine serum protein binding in healthy subjects. Clin Pharmacol Ther 1983;34:689-94. (Pubitemid 14247729)
12. Voulgari F, Cummins P, Gardecki TI, Beeching NJ, Stone PC, Stuart J. Serum levels of acute phase and cardiac proteins after myocardial infarction, surgery, and infection. Br Heart J 1982;48:352-6. (Pubitemid 12032590)
13. Dudley MN, Blaser J, Gilbert D, Zinner SH. Significance of extravascular protein binding for antimicrobial pharmacodynamics in an in vitro capillary model of infection. Antimicrob Agents Chemother 1990;34:98-101. (Pubitemid 20019971)
14. Greenblatt DJ, Sellers EM, Koch-Weser J. Importance of protein binding for the interpretation of serum or plasma drug concentrations. J Clin Pharmacol 1982;22:259-63. (Pubitemid 12081305)
15. Lee BL, Sachdeva M, Chambers HF. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother 1991;35:2505-8.
16. Merrikin DJ, Briant J, Rolinson GN. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother 1983;11:233-8. (Pubitemid 13161697)
17. Nix DE, Matthias KR, Ferguson EC. Effect of ertapenem protein binding on killing of bacteria. Antimicrob Agents Chemother 2004;48:3419-24. (Pubitemid 39129340)
18. Schmidt S, Rock K, Sahre M, Burkhardt O, Brunner M, Lobmeyer MT, et al. Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob Agents Chemother 2008;52:3994-4000.
19. Wise R. The relevance of pharmacokinetics to in-vitro models: protein binding-does it matter? J Antimicrob Chemother 1985;15(Suppl. A):77-83. (Pubitemid 15079549)
20. Wise R. The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clin Pharmacokinet 1986;11:470-82. (Pubitemid 17203069)
21. Dente L, Ciliberto G, Cortese R. Structure of the human alpha 1-acid glycoprotein gene: sequence homology with other human acute phase protein genes. Nucleic Acids Res 1985;13:3941-52.
22. Dente L, Pizza MG, Metspalu A, Cortese R. Structure and expression of the genes coding for human alpha 1-acid glycoprotein. EMBO J 1987;6:2289-96.
23. Dente L, Ruther U, Tripodi M, Wagner EF, Cortese R. Expression of human alpha 1-acid glycoprotein genes in cultured cells and in transgenic mice. Genes Dev 1988;2:259-66.
24. Eap CB, Fischer JF, Baumann P. Variations in relative concentrations of variants of human alpha 1-acid glycoprotein after acute-phase conditions. Clin Chim Acta 1991;203:379-85.
25. Herve F, Gomas E, Duche JC, Tillement JP. Fractionation of the genetic-variants of human Alpha(1)-acid glycoprotein in the native form by chromatography on an immobilized copper(ii) affinity adsorbent - heterogeneity of the separate variants by isoelectrofocusing and by concanavalin-a affinity-chromatography. J Chromatogr Biomed Appl 1993;615:47-57. (Pubitemid 23161296)
26. Nishi K, Ono T, Nakamura T, Fukunaga N, Izumi M, Watanabe H, et al. Structural insights into differences in drug-binding selectivity between two forms of human alpha1-acid glycoprotein genetic variants, the A and F1*S forms. J Biol Chem 2011;286:14427-34.
27. Schonfeld DL, Ravelli RB, Mueller U, Skerra A. The 1.8-A crystal structure of alpha1-acid glycoprotein (Orosomucoid) solved by UV RIP reveals the broad drug-binding activity of this human plasma lipocalin. J Mol Biol 2008;384:393-405.
28. Flower DR. Experimentally determined lipocalin structures. Biochim Biophys Acta 2000;1482:46-56.
29. Schmid K, Nimerg RB, Kimura A, Yamaguchi H, Binette JP. The carbohydrate units of human plasma alpha1-acid glycoprotein. Biochim Biophys Acta 1977;492:291-302. (Pubitemid 8115970)
30. Nakano M, Kakehi K, Tsai MH, Lee YC. Detailed structural features of glycan chains derived from alpha1-acid glycoproteins of several different animals: the presence of hypersialylated, O-acetylated sialic acids but not disialyl residues. Glycobiology 2004;14:431-41. (Pubitemid 38744924)
31. Treuheit MJ, Costello CE, Halsall HB. Analysis of the five glycosylation sites of human alpha 1-acid glycoprotein. Biochem J 1992;283(Pt 1):105-12.
32. Li J, Nation RL. Old polymyxins are back: is resistance close. Clin Infect Dis 2006;43:663-4. (Pubitemid 44267132)
33. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant in Gram-negative bacteria. Int J Antimicrob Agents 2005;25:11-25. (Pubitemid 40023341)
34. Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007;45:594-8. (Pubitemid 47328640)
35. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601.
36. Nation RL, Li J. Optimizing use of colistin and polymyxin B in the critically ill. Semin Respir Crit Care Med 2007;28:604-14.
37. Vaara M, Vaara T. Structure-activity studies on novel polymyxin derivatives that carry only three positive charges. Peptides 2010;31:2318-21.
38. Velkov T, Thompson PE, Nation RL, Li J. Structure-activity relationships of polymyxin antibiotics. J Med Chem 2010;53:1898-916.
39. Hancock RE, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother 1999;43:1317-23. (Pubitemid 29259318)
40. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003;47:1766-70. (Pubitemid 36548571)
41. Dudhani RV, Li J, Nation RL. Plasma binding of colistin involves multiple proteins and is concentration dependent: potential clinical implications. In: Abstracts of the forty-ninth interscience conference on antimicrobial agents and chemotherapy. Washington, DC, USA: American Society for Microbiology; 2009. p. 41.
42. Danner RL, Joiner KA, Rubin M, Patterson WH, Johnson N, Ayers KM, et al. Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrob Agents Chemother 1989;33:1428-34. (Pubitemid 19227990)
43. Soon RL, Velkov T, Chiu F, Thompson PE, Kancharla R, Roberts K, et al. Design, synthesis, and evaluation of a new fluorescent probe for measuring polymyxin-lipopolysaccharide binding interactions. Anal Biochem 2011;409:273-83.
44. Velkov T, Lim ML, Capuano B, Prankerd R. A protocol for the combined subfractionation and delipidation of lipid binding proteins using hydrophobic interaction chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2008;867:238-46.
45. Freyer MW, Lewis EA. Isothermal titration calorimetry: experimental design, data analysis, and probing macromolecule/ligand binding and kinetic interactions. Methods Cell Biol 2008;84:79-113.
46. Pristovsek P, Kidric J. The search for molecular determinants of LPS inhibition by proteins and peptides. Curr Top Med Chem 2004;4:1185-201. (Pubitemid 38923441)
47. Breustedt DA, Schonfeld DL, Skerra A. Comparative ligand-binding analysis of ten human lipocalins. Biochim Biophys Acta 2006;1764:161-73.
48. Brown MB, Miller JN, Seare NJ. An investigation of the use of Nile-Red as a long-wavelength fluorescent-probe for the study of alpha(1)-acid glycoprotein-drug interactions. J Pharm Biomed Anal 1995;13:1011-7.
49. Essassi D, Zini R, Tillement JP. Use of 1-anilino-8-naphthalene sulfonate as a fluorescent probe in the investigation of drug interactions with human alpha-1-acid glycoprotein and serum albumin. J Pharm Sci 1990;79:9-13. (Pubitemid 20148505)
50. Johansen AK, Willassen NP, Sager G. Fluorescence studies of beta-adrenergic ligand binding to alpha 1-acid glycoprotein with 1-anilino-8-naphthalene sulfonate, isoprenaline, adrenaline and propranolol. Biochem Pharmacol 1992;43:725-9.
51. Sugiyama Y, Suzuki Y, Sawada Y, Kawasaki S, Beppu T, Iga T, et al. Auramine O as a fluorescent probe for the binding of basic drugs to human alpha 1-acid glycoprotein (alpha 1-AG). The development of a simple fluorometric method for the determination of alpha 1-AG in human serum. Biochem Pharmacol 1985;34:821-9. (Pubitemid 15107175)
52. Matsumoto K, Sukimoto K, Nishi K, Maruyama T, Suenaga A, Otagiri M. Characterization of ligand binding sites on the alpha1-acid glycoprotein in humans, bovines and dogs. Drug Metab Pharmacokinet 2002;17:300-6.
53. Zini R, Copigneaux C, Tillement JP. 1-Anilino-naphthalene 8-sulfonic acid (ANS) as a probe for the binding of antidepressant drugs to human alpha 1-acid glycoprotein (AAG). Prog Clin Biol Res 1989;300:417-21.
54. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 2003;47:1364-70. (Pubitemid 36368598)
55. Prabhu NV, Sharp KA. Heat capacity in proteins. Annu Rev Phys Chem 2005;56:521-48. (Pubitemid 41156887)
56. Wallace SJ, Li J, Nation RL, Prankerd RJ, Velkov T, Boyd BJ. Self-assembly behavior of colistin and its prodrug colistin methanesulfonate: implications for solution stability and solubilization. J Phys Chem B 2010;114:4836-40.
57. Gennari HVaFJ. Acid-base disorders, basic concepts and clinical management. Boston: Little, Brown and Company; 1986.
58. Ross PD, Subramanian S. Thermodynamics of protein association reactions: forces contributing to stability. Biochemistry 1981;20:3096-102.
59. Lin Z, Schwartz FP, Eisenstein E. The hydrophobic nature of GroEL-substrate binding. J Biol Chem 1995;270:1011-4.
60. Perozzo R, Folkers G, Scapozza L. Thermodynamics of protein-ligand interactions: history, presence, and future aspects. J Recept Signal Transduct Res 2004;24:1-52. (Pubitemid 39011288)
61. Chen W-Y, Huang H-M, Lin C-C, Lin F-Y, Chan Y-C. Effect of temperature on hydrophobic interaction between proteins and hydrophobic adsorbents: studies by isothermal titration calorimetry and the van't Hoff equation. Langmuir 2003;19:9395-403.
62. Ladbury JE. Just add water! The effect of water on the specificity of protein-ligand binding sites and its potential application to drug design. Chem Biol 1996;3:973-80. (Pubitemid 27058821)
63. Lemieux RU. How water provides the impetus for molecular recognition in aqueous solution. Acc Chem Res 1996;29:373-80. (Pubitemid 126453219)
64. Herve F, Caron G, Duche JC, Gaillard P, Rahman NA, Tsantili-Kakoulidou A, et al. Ligand specificity of the genetic variants of human alpha(1)-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the a variant. Mol Pharmacol 1998;54:129-38. (Pubitemid 28337595)
65. Herve F, Duche JC, d'Athis P, Marche C, Barre J, Tillement JP. Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics 1996;6:403-15. (Pubitemid 26380096)
66. Berg JR, Spilker CM, Lewis SA. Effects of polymyxin B on mammalian urinary bladder. J Membr Biol 1996;154:119-30. (Pubitemid 26413995)
67. Eap CB, Cuendet C, Baumann P. Binding of amitriptyline to alpha 1-acid glycoprotein and its variants. J Pharm Pharmacol 1988;40:767-70.
68. Eap CB, Cuendet C, Baumann P. Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 1988;337:220-4. (Pubitemid 18076721)
69. Eap CB, Cuendet C, Baumann P. Binding of D-methadone, L-methadone, and DL-methadone to proteins in plasma of healthy volunteers: role of the variants of α1-acid glycoprotein. Clin Pharmacol Ther 1990;47:338-46. (Pubitemid 20115020)
70. Herve F, Caron G, Duche JC, Gaillard P, Abd Rahman N, Tsantili-Kakoulidou A, et al. Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant. Mol Pharmacol 1998;54:129-38. (Pubitemid 28337595)
71. Herve F, Gomas E, Duche JC, Tillement JP. Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein. Br J Clin Pharmacol 1993;36:241-9. (Pubitemid 23275342)
72. Ishizaki J, Fukaishi A, Fukuwa C, Yamazaki S, Tabata M, Ishida T, et al. Evaluation of selective competitive binding of basic drugs to alpha1-acid glycoprotein variants. Biol Pharm Bull 2010;33:95-9.
73. Nakagawa T, Kishino S, Itoh S, Sugawara M, Miyazaki K. Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants. Br J Clin Pharmacol 2003;56:664-9. (Pubitemid 37491719)
74. Zavascki AP, Goldani LZ, Cao GY, Superti SV, Lutz L, Barth AL, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 2008;47:1298-304.
75. Kwa ALH, Lim TP, Low JGH, Hou J, Kurup A, Prince RA, et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis 2008;60:163-7.
76. Peters Jr T. All about albumin: biochemistry, genetics, and medical applications. San Diego: Academic Press; 1996.